Disease · MONDO_0011438

acne

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. acne. Diseases, record MONDO_0011438. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0011438

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: acne; Open Targets
Open Targets ID: MONDO_0011438; Open Targets
Other names: acne (disease), acne varioliformis, acne vulgaris; Open Targets
Disease Ontology: DOID:6543; Disease Ontology
NCI Thesaurus: C27195; NCI Thesaurus
Highest stage of its drugs: Approval, for 57 of its 135 drugs, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs135

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BENZOYL PEROXIDE	CHEMBL1200370	Small molecule	Approval	ATC, DailyMed, PMDA and TTD	136	100	100	Drugs and targets
ADAPALENE	CHEMBL1265	Small molecule	Approval	ATC, DailyMed, PMDA and TTD	116	87	87	Drugs and targets
TRETINOIN	CHEMBL38	Small molecule	Approval	ATC, DailyMed and TTD	88	41	41	Drugs and targets
CLINDAMYCIN	CHEMBL1753	Small molecule	Approval	ATC, PMDA and TTD	42	38	37	Drugs and targets
CLINDAMYCIN PHOSPHATE	CHEMBL3184512	Small molecule	Approval	DailyMed, PMDA and TTD	76	34	34	Drugs and targets
TAZAROTENE	CHEMBL1657	Small molecule	Approval	DailyMed	31	23	23	Drugs and targets
ISOTRETINOIN	CHEMBL547	Small molecule	Approval	ATC and TTD	27	23	23	Drugs and targets
DAPSONE	CHEMBL1043	Small molecule	Approval	ATC and DailyMed	25	23	23	Drugs and targets
DOXYCYCLINE	CHEMBL1200699	Small molecule	Approval	DailyMed	56	16	16	Drugs and targets
CLASCOTERONE	CHEMBL3590187	Small molecule	Approval	ATC, EMA Human Drugs and TTD	17	14	13	Drugs and targets

1 to 10 of 135

See all 135 drugs

Targets116

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
AR	Androgen receptor	5	Androgen Receptor agonist; Androgen Receptor antagonist; Androgen Receptor degrader	Approval	https://conductscience.org/library/genes/367	Drugs and targets
NR3C1	Glucocorticoid receptor	5	Glucocorticoid receptor agonist; Glucocorticoid receptor antagonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
RARG	Retinoic acid receptor	5	Retinoic acid receptor agonist; Retinoic acid receptor gamma agonist	Approval	https://conductscience.org/library/genes/5916	Drugs and targets
PGR	Progesterone receptor	4	Progesterone receptor agonist	Approval	https://conductscience.org/library/genes/5241	Drugs and targets
RARA	Retinoic acid receptor	4	Retinoic acid receptor agonist	Approval	https://conductscience.org/library/genes/5914	Drugs and targets
RARB	Retinoic acid receptor	4	Retinoic acid receptor agonist	Approval	https://conductscience.org/library/genes/5915	Drugs and targets
ACACA	Acetyl-CoA carboxylase	2	Acetyl-CoA carboxylase inhibitor	Phase 3	https://conductscience.org/library/genes/31	Drugs and targets
ACACB	Acetyl-CoA carboxylase	2	Acetyl-CoA carboxylase inhibitor	Phase 3	https://conductscience.org/library/genes/32	Drugs and targets
MMP1	Interstitial collagenase	2	Matrix metalloproteinase-1 inhibitor	Approval	https://conductscience.org/library/genes/4312	Drugs and targets
MMP13	Collagenase 3	2	Matrix metalloproteinase 13 inhibitor	Approval	https://conductscience.org/library/genes/4322	Drugs and targets

1 to 10 of 116

See all 116 targets

Trials350

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 12 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01974323	Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris	Phase 3	2,238	2017-02-06	Acne Vulgaris	DAPSONE	Its record names the disease	ClinicalTrials.gov
NCT01974141	A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris	Phase 3	2,102	2017-02-06	Acne Vulgaris	DAPSONE	Its record names the disease	ClinicalTrials.gov
NCT00421993	A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris	Phase 3	1,670	2009-03-11	Acne Vulgaris	ADAPALENE, BENZOYL PEROXIDE	Its record names the disease	ClinicalTrials.gov
NCT00422240	Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris	Phase 3	1,668	2024-04-15	Acne Vulgaris	ADAPALENE, BENZOYL PEROXIDE	Its record names the disease	ClinicalTrials.gov
NCT00689117	A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel	Phase 3	1,649	2010-12-02	Acne Vulgaris, Acne	CLINDAMYCIN, TRETINOIN	Its record names the disease	ClinicalTrials.gov
NCT01138514	Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels	Phase 3	1,555	2016-03-29	Acne Vulgaris	BENZOYL PEROXIDE, CLINDAMYCIN	Its record names the disease	ClinicalTrials.gov
NCT03271021	A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris	Phase 3	1,488	2020-02-21	Acne Vulgaris	MINOCYCLINE	Its record names the disease	ClinicalTrials.gov
NCT02667444	P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne	Phase 3	1,330	2023-07-24	Acne Vulgaris	BERDAZIMER SODIUM	Its record names the disease	ClinicalTrials.gov
NCT00776919	Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne	Phase 3	1,315	2012-01-30	Acne Vulgaris	BENZOYL PEROXIDE, CLINDAMYCIN	Its record names the disease	ClinicalTrials.gov
NCT02672332	P3 Study in Acne Comparing Once Daily SB204 and Vehicle	Phase 3	1,307	2023-05-06	Acne Vulgaris	BERDAZIMER SODIUM	Its record names the disease	ClinicalTrials.gov

1 to 10 of 350

See all 350 trials

Comparisons in its trials135

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Dapsone Gel vs Dapsone Gel Vehicle: serious adverse events	4 of 1,117	4 of 1,118	2,235	NCT01974323	Trial comparisons
Dapsone Gel vs Dapsone Gel Vehicle: serious adverse events	3 of 1,044	5 of 1,057	2,101	NCT01974141	Trial comparisons
FMX101, 4% Minocycline Foam vs Vehicle Foam: IGA Treatment Success (Dichotomized as Yes/no) at Week 6, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 6	84 of 738	46 of 750	1,488	NCT03271021	Trial comparisons
FMX101, 4% Minocycline Foam vs Vehicle Foam: Investigator Global Assessment (IGA) Treatment Success (Dichotomized as Yes/no) at Week 12, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline	199 of 738	133 of 750	1,488	NCT03271021	Trial comparisons
FMX101, 4% Minocycline Foam vs Vehicle Foam: IGA Treatment Success (Dichotomized as Yes/no) at Week 9, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 9	137 of 738	79 of 750	1,488	NCT03271021	Trial comparisons
FMX101, 4% Minocycline Foam vs Vehicle Foam: deaths from any cause	0 of 737	0 of 747	1,484	NCT03271021	Trial comparisons
FMX101, 4% Minocycline Foam vs Vehicle Foam: serious adverse events	1 of 737	4 of 747	1,484	NCT03271021	Trial comparisons
SB204 4% vs Vehicle Gel: deaths from any cause	0 of 666	0 of 661	1,327	NCT02667444	Trial comparisons
SB204 4% vs Vehicle Gel: serious adverse events	1 of 666	3 of 661	1,327	NCT02667444	Trial comparisons
SB204 4% vs Vehicle Gel: deaths from any cause	0 of 654	1 of 652	1,306	NCT02672332	Trial comparisons

1 to 10 of 135

See all 135 comparisons in its trials

Papers from its trials76

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38380975	RESULT	1	PubMed
33548303	RESULT	1	PubMed
31163231	RESULT	1	PubMed
29369333	RESULT	1	PubMed
29036256	RESULT	1	PubMed
28573779	RESULT	1	PubMed
27514932	RESULT	1	PubMed
27177989	RESULT	1	PubMed
26897386	RESULT	1	PubMed
24918554	RESULT	1	PubMed

1 to 10 of 76

See all 76 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0011438

GET https://conductscience.org/api/diseases/v1/MONDO_0011438/drugs?page=2

API reference For AI assistants